Treatment Details – 4.8 months

Survival: 4.8 months
  
Toxicity Grade:5
  
Treatments: Chemotherapy
  
Drugs: Adriamycin
Country:United States
  
City/State/Province:La Jolla, California
  
Hospital:Scripps Clinic
  
Journal:Link
  
Date: 11/2001

Description:
Patients: This Phase II study involved 10 patients with malignant mesothelioma.

Treatment: The treatment consisted of the chemotherapy drug doxorubicin (adriamycin) (high-dose) with the drugs dexrazoxane (for cardio-protection), and GM-CSF (to lessen bone marrow toxicity).

Toxicity: One patient died of sepsis. In addition, grade 3-4 toxicities included hematologic, infection, esophagitis/dysphagia, and cardiac function. This study was terminated early due to excessive toxicity.

Results: No patient responded to treatment and the median overall survival was 4.8 months.

Correspondence: Michael P. Kosty, MD

Get your free copy of
“Surviving Mesothelioma” Today!